Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 May 23:S2152-2650(23)00166-0. doi: 10.1016/j.clml.2023.05.008. Online ahead of print.ABSTRACTSecondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor antibody function. SAD is common in patients with multiple myeloma (MM) due to underlying disease pathophysiology and treatment-related immune system effects. Patients with SAD are more susceptible to infections and infection-related morbidity and mortality. With therapeutic advancements improving MM disease control and survival, it is incr...
Source: Clinical Lymphoma and Myeloma - June 23, 2023 Category: Cancer & Oncology Authors: Sergio Giralt Stephen Jolles Tessa Kerre Hillard M Lazarus S Shahzad Mustafa Genovefa A Papanicolaou Roberto Ria Donald C Vinh John R Wingard Source Type: research
SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00188-X. doi: 10.1016/j.clml.2023.06.006. Online ahead of print.ABSTRACTClassic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the fro...
Source: Clinical Lymphoma and Myeloma - June 21, 2023 Category: Cancer & Oncology Authors: Karan L Chohan Stephen M Ansell Source Type: research
SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00188-X. doi: 10.1016/j.clml.2023.06.006. Online ahead of print.ABSTRACTClassic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the fro...
Source: Clinical Lymphoma and Myeloma - June 21, 2023 Category: Cancer & Oncology Authors: Karan L Chohan Stephen M Ansell Source Type: research
SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00188-X. doi: 10.1016/j.clml.2023.06.006. Online ahead of print.ABSTRACTClassic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the fro...
Source: Clinical Lymphoma and Myeloma - June 21, 2023 Category: Cancer & Oncology Authors: Karan L Chohan Stephen M Ansell Source Type: research
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis
CONCLUSION: Despite the limitations, thiotepa-based autoHCT in CR1 appears to improve outcomes in eligible patients with PCNSL.PMID:37336714 | DOI:10.1016/j.clml.2023.06.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 19, 2023 Category: Cancer & Oncology Authors: Tamer Othman Michelle A Quan Shiliang Zhang Daria Gaut Patricia A Young Omar Mahmood Haifaa Abdulhaq Kevin Shieh Jack Reid Elizabeth A Brem Nisha Hariharan Benjamin Heyman Joseph Tuscano Source Type: research
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis
CONCLUSION: Despite the limitations, thiotepa-based autoHCT in CR1 appears to improve outcomes in eligible patients with PCNSL.PMID:37336714 | DOI:10.1016/j.clml.2023.06.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 19, 2023 Category: Cancer & Oncology Authors: Tamer Othman Michelle A Quan Shiliang Zhang Daria Gaut Patricia A Young Omar Mahmood Haifaa Abdulhaq Kevin Shieh Jack Reid Elizabeth A Brem Nisha Hariharan Benjamin Heyman Joseph Tuscano Source Type: research
External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse
CONCLUSION: The FLIPI score measured at diagnosis may help with the risk stratification of individuals with relapsed FL.PMID:37331847 | DOI:10.1016/j.clml.2023.05.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 18, 2023 Category: Cancer & Oncology Authors: Devon J Boyne Neil Chua Carolyn Owen Ofodile Joe-Uzuegbu Huma Shakir Priyanka Gogna Tamer N Jarada Darren R Brenner Julia Elia-Pacitti Emmanuel M Ewara Winson Y Cheung Source Type: research
External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse
CONCLUSION: The FLIPI score measured at diagnosis may help with the risk stratification of individuals with relapsed FL.PMID:37331847 | DOI:10.1016/j.clml.2023.05.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 18, 2023 Category: Cancer & Oncology Authors: Devon J Boyne Neil Chua Carolyn Owen Ofodile Joe-Uzuegbu Huma Shakir Priyanka Gogna Tamer N Jarada Darren R Brenner Julia Elia-Pacitti Emmanuel M Ewara Winson Y Cheung Source Type: research
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
CONCLUSION: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.PMID:37308342 | DOI:10.1016/j.clml.2023.05.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 12, 2023 Category: Cancer & Oncology Authors: Georgina Gener-Ricos Fadi G Haddad Koji Sasaki Ghayas C Issa Jeffrey Skinner Lucia Masarova Gautam Borthakur Yesid Alvarado Guillermo Garcia-Manero Elias Jabbour Hagop Kantarjian Source Type: research
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
CONCLUSION: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.PMID:37308342 | DOI:10.1016/j.clml.2023.05.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 12, 2023 Category: Cancer & Oncology Authors: Georgina Gener-Ricos Fadi G Haddad Koji Sasaki Ghayas C Issa Jeffrey Skinner Lucia Masarova Gautam Borthakur Yesid Alvarado Guillermo Garcia-Manero Elias Jabbour Hagop Kantarjian Source Type: research
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
CONCLUSION: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.PMID:37308342 | DOI:10.1016/j.clml.2023.05.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 12, 2023 Category: Cancer & Oncology Authors: Georgina Gener-Ricos Fadi G Haddad Koji Sasaki Ghayas C Issa Jeffrey Skinner Lucia Masarova Gautam Borthakur Yesid Alvarado Guillermo Garcia-Manero Elias Jabbour Hagop Kantarjian Source Type: research
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
CONCLUSION: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.PMID:37308342 | DOI:10.1016/j.clml.2023.05.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 12, 2023 Category: Cancer & Oncology Authors: Georgina Gener-Ricos Fadi G Haddad Koji Sasaki Ghayas C Issa Jeffrey Skinner Lucia Masarova Gautam Borthakur Yesid Alvarado Guillermo Garcia-Manero Elias Jabbour Hagop Kantarjian Source Type: research
SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas
Clin Lymphoma Myeloma Leuk. 2023 May 23:S2152-2650(23)00170-2. doi: 10.1016/j.clml.2023.05.012. Online ahead of print.ABSTRACTMature T- and NK-cell neoplasms (MTNKN) collectively represent a rare disorder, representing less than 15% of all non-Hodgkin lymphoma (NHL) cases and qualifying for orphan disease designation by the U.S. Food and Drug Administration (FDA). These consist of 9 families in the fifth revised WHO classification of lymphoid neoplasms, which are made up of over 30 disease subtypes, underscoring the heterogeneity of clinical features, molecular biology, and genetics across this disease group. Moreover, the...
Source: Clinical Lymphoma and Myeloma - June 11, 2023 Category: Cancer & Oncology Authors: Rahul S Bhansali Stefan K Barta Source Type: research
SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas
Clin Lymphoma Myeloma Leuk. 2023 May 23:S2152-2650(23)00170-2. doi: 10.1016/j.clml.2023.05.012. Online ahead of print.ABSTRACTMature T- and NK-cell neoplasms (MTNKN) collectively represent a rare disorder, representing less than 15% of all non-Hodgkin lymphoma (NHL) cases and qualifying for orphan disease designation by the U.S. Food and Drug Administration (FDA). These consist of 9 families in the fifth revised WHO classification of lymphoid neoplasms, which are made up of over 30 disease subtypes, underscoring the heterogeneity of clinical features, molecular biology, and genetics across this disease group. Moreover, the...
Source: Clinical Lymphoma and Myeloma - June 11, 2023 Category: Cancer & Oncology Authors: Rahul S Bhansali Stefan K Barta Source Type: research
Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population
CONCLUSION: Disease-targeted interventions to address high acute health care utilization is needed amongst AYAs. Additionally, early multidisciplinary involvement after cancer diagnosis particularly with psychiatric expertise amongst AYAs and palliative care involvement in both groups is needed.PMID:37301630 | DOI:10.1016/j.clml.2023.05.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Kriti Thapa Myla Strawderman Patrick M Reagan Paul M Barr Clive S Zent Jonathan W Friedberg Tina Faugh Carla Casulo Source Type: research
